Human Thyroid Cancer Tissue Lysates
Pricing |
Normal Lysates: $125/100 ug |
Tumor Lysates: $175/100 ug |
Nor./Tum. set: $270.00 (10% off) |
Discounts |
2-8 Vials 10% |
9-20 Vials 15% |
>20 Vials 20% |
Introduction:
Histologic types of thyroid cancer include the following:
Cell type is an important determinant of prognosis in thyroid cancer. There are 4 main varieties of thyroid cancer (although, for clinical management of the patient, thyroid cancer is generally divided into 2 categories, well differentiated or poorly differentiated).
Papillary carcinoma - Papillary/follicular carcinoma.
Follicular carcinoma - H�rthle cell carcinoma.
Medullary carcinoma.
Anaplastic carcinoma - Small cell carcinoma, Giant cell carcinoma.
Others - Lymphoma, Sarcoma, Carcinosarcoma.
Human Thyroid Cancer Lysates | ||||||
Catalog Number |
Diagnosis |
Grade |
Stage |
TNM |
Sex |
Age |
Papillary carcinoma |
n/a |
n/a |
n/a |
M |
n/a |
|
Thyroid carcinoma |
n/a |
n/a |
n/a |
F |
n/a |
|
Follicular carcinoma |
n/a |
III |
T3N1bM0 |
F |
14 |
|
Medullary carcinoma |
n/a |
n/a |
n/a |
F |
5 |
|
Papillary carcinoma |
n/a |
n/a |
n/a |
F |
49 |
|
Papillary adenocarcinoma |
n/a |
III |
T2N1M0 |
F |
53 |
|
Papillary carcinoma |
n/a |
III |
T3N1M0 |
F |
30 |
|
Benign colloid nodules |
n/a |
n/a |
n/a |
F |
72 |
|
Papillary carcinoma |
1 |
n/a |
T2N1aM0 |
F |
18 |
|
Papillary carcinoma |
n/a |
III |
T3N1M0 |
M |
25 |
|
Papillary carcinoma |
n/a |
II |
T2N1M0 |
M |
39 |
|
Papillary cystadenocarcinoma |
n/a |
n/a |
T1bNxM0 |
F |
46 |
|
Papillary carcinoma |
n/a |
II |
T2N1M0 |
M |
42 |
|
Papillary carcinoma |
n/a |
n/a |
n/a |
F |
38 |
|
Papillary carcinoma |
1 |
n/a |
n/a |
F |
58 |
|
Papillary carcinoma |
1 |
I |
T1N0Mx |
M |
64 |
|
Adenocystic carcinoma |
2 |
IIB |
T2N1M0 |
M |
67 |
|
Papillary adenocystic carcinoma |
n/a |
II |
T2N1M0 |
F |
32 |
|
Papillary carcinoma |
1 |
n/a |
n/a |
F |
73 |
|
Papillary carcinoma |
1 |
II |
n/a |
F |
66 |
|
Papillary carcinoma |
1 |
II |
n/a |
M |
21 |
|
Papillary carcinoma |
1 |
1 |
n/a |
F |
22 |
|
Papillary carcinoma |
1 |
II |
T2N0Mx |
F |
46 |
|
Medullary carcinoma |
2 |
III |
T3N1Mx |
F |
38 |
|
Medullary carcinoma |
2 |
n/a |
n/a |
F |
56 |
|
Thyroid carcinoma |
2 |
II |
T2N0Mx |
F |
49 |
|
Medullary carcinoma |
2 |
III |
T2N1Mx |
F |
21 |
|
Papillary carcinoma |
1 |
1 |
T1N0Mx |
F |
35 |
|
Papillary carcinoma |
1 |
II |
T2N0Mx |
F |
22 |
|
Papillary carcinoma |
1 |
II |
T2N0Mx |
F |
70 |
|
Papillary carcinoma |
1 |
II |
T2N0Mx |
M |
56 |
|
Papillary carcinoma |
1 |
II |
T2N0Mx |
F |
44 |
|
Papillary carcinoma |
2 |
III |
T2N1M0 |
F |
24 |
|
Papillary carcinoma |
n/a |
III |
T3N1M0 |
F |
38 |
|
Thyroid carcinoma |
n/a |
n/a |
n/a |
M |
32 |
References:
Mostofi FK, Davis CJ, Sesterhenn IA: Pathology of tumors of the urinary tract. In: Skinner DG, Lieskovsky G, eds.: Diagnosis and Management of Genitourinary Cancer. Philadelphia, Pa: WB Saunders, 1988., pp 83-117.
Wilson TG, Pritchett TR, Lieskovsky G, et al.: Primary adenocarcinoma of bladder. Urology 38 (3): 223-6, 1991.
LiVolsi VA: Pathology of thyroid disease. In: Falk SA: Thyroid Disease: Endocrinology, Surgery, Nuclear Medicine, and Radiotherapy. Philadelphia, PA: Lippincott-Raven, 1997., pp 127-175.